United States Government Publishing Office
publisher
pbl
distributor
dst
United States
National Archives and Records Administration
Office of the Federal Register
author
aut
Government Organization
text
government publication
eng
FR
Regulatory Information
2000_register
executive
2010-09-24
article
National Cancer Institute: Development of Innovative Idiotype Tumor Vaccines
Notices
D09002ee1bdfa86e2
D09002ee1bdfa8768
United States
Department of Health and Human Services
originator
org
United States Government Agency or Subagency
United States
National Institutes of Health
originator
org
United States Government Agency or Subagency
Pursuant to the Federal Technology Transfer Act of 1986 (FTTA, 15 U.S.C. 3710; Executive Order 12591 of April 10, 1987 as amended by the National Technology Transfer and Advancement Act of 1995), the National Cancer Institute (NCI) of the National Institutes of Health (NIH) of the Public Health Service (PHS) of the Department of Health and Human Services (DHHS) is seeking pharmaceutical or biotechnology companies which can effectively collaborate on the scientific and commercial development of idiotypic tumor vaccines for treatment of low-grade and intermediate B-cell lymphomas, mantle cell lymphoma or chronic lymphocytic leukemia (CLL). The goal of the collaboration(s) will be the development of novel vaccine strategies to elicit an immune response directed against autologous idiotypic surface immunoglobulin derived from these tumors. Any CRADA for further development of this technology that focuses on preclinical or clinical studies of idiotypic vaccines for treatment of the indicated diseases will be considered. The CRADA would have an expected duration of three (3) to five (5) years. The goals of the CRADA will include the rapid publication of research results and timely commercialization of products, diagnostics, and treatments that result from the research. The CRADA Collaborators will have an option to negotiate the terms of an exclusive or nonexclusive commercialization license to subject inventions arising under the CRADA.
65 FR 39151
https://www.govinfo.gov/app/details/FR-2000-06-23/00-15939
00-15939
fr23jn00-70
4140-01-P
https://www.govinfo.gov/app/details/FR-2000-06-23/00-15939
https://www.govinfo.gov/content/pkg/FR-2000-06-23/html/00-15939.htm
https://www.govinfo.gov/content/pkg/FR-2000-06-23/pdf/00-15939.pdf
2 p.
39151
39152
65 FR 39151
National Cancer Institute: Development of Innovative Idiotype Tumor Vaccines; Federal Register Vol. 65, Issue
NOTICE
00-15939
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
4140-01-P
00-15939
Notice of opportunities for Cooperative Research and Development Agreements.
Pursuant to the Federal Technology Transfer Act of 1986 (FTTA, 15 U.S.C. 3710; Executive Order 12591 of April 10, 1987 as amended by the National Technology Transfer and Advancement Act of 1995), the National Cancer Institute (NCI) of the National Institutes of Health (NIH) of the Public Health Service (PHS) of the Department of Health and Human Services (DHHS) is seeking pharmaceutical or biotechnology companies which can effectively collaborate on the scientific and commercial development of idiotypic tumor vaccines for treatment of low-grade and intermediate B-cell lymphomas, mantle cell lymphoma or chronic lymphocytic leukemia (CLL). The goal of the collaboration(s) will be the development of novel vaccine strategies to elicit an immune response directed against autologous idiotypic surface immunoglobulin derived from these tumors. Any CRADA for further development of this technology that focuses on preclinical or clinical studies of idiotypic vaccines for treatment of the indicated diseases will be considered. The CRADA would have an expected duration of three (3) to five (5) years. The goals of the CRADA will include the rapid publication of research results and timely commercialization of products, diagnostics, and treatments that result from the research. The CRADA Collaborators will have an option to negotiate the terms of an exclusive or nonexclusive commercialization license to subject inventions arising under the CRADA.
Organizations must submit a proposal summary preferably two pages or less, to NCI within 90 days from date of this publication. Guidelines for preparing full CRADA proposals will be communicated shortly thereafter to all respondents with whom initial discussions have established sufficient mutual interest.
Grants and cooperative agreements; availability, etc.:
National Cancer Institute
Innovative idotype tumor vaccines,
Federal Register
Vol. 65, no. 122
Office of the Federal Register, National Archives and Records Administration
2000-06-23
continuing
daily
deposited
born digital
219 p.
Table of Contents:
AE 2.7:
GS 4.107:
AE 2.106:
KF70.A2
https://www.govinfo.gov/app/details/FR-2000-06-23
P0b002ee1809ffa33
0097-6326
0042-1219
0364-1406
769-004-00000-9
000582072
f:fr23jn00
https://www.govinfo.gov/app/details/FR-2000-06-23
https://www.govinfo.gov/content/pkg/FR-2000-06-23/pdf/FR-2000-06-23.pdf
https://www.govinfo.gov/content/pkg/FR-2000-06-23/xml/FR-2000-06-23.xml
fdlp
39071
39277
DGPO
2010-09-24
2023-05-05
FR-2000-06-23
machine generated
eng
FR
FR-2000-06-23
65
122